Effect of white blood cells enhancing factor on medulloblastoma (Brain tumor) patients receiving radiotherapy

Impact of prophylactic granulocyte-colony stimulating factor on acute hematolohical toxicity in patients of medulloblastoma receiving craniospinal irradiation (CSI): A prospective study

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/01/011292

Enrollment

Registered

2018-01-12

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Medulloblastoma patients receiving radiotherapy

Interventions

Intervention1: Inj Granulocyte colony stimulating factor (G-CSF): Inj Granulocyte colony stimulating factor (G-CSF) will be given prophylactically during Radiotherapy Control Intervention1: Previously

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1. >3 years of age 2. Post-operative 3. Histologically proven medulloblastoma

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
To study the impact of administration of prophylactic G-CSF on acute hematological toxicity during CSI in patients of MedulloblastomaTimepoint: Toxicity will be assessed every week during Radiotherapy	—

Secondary

Measure	Time frame
1. Survival analysis 2. Assessment of long-term toxicities Timepoint: 3 months after last chemotherapy and yearly afterwards for 5 years	—

Countries

India

Contacts

Public ContactDr Renu Madan

Postgraduate Institute of Medical Education and Research

renumadan10@yahoo.com9868597027

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026